Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CTNM with free AI briefings, catalyst countdowns, and dilution alerts.

CTNM · Contineum Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$244.5M Cash on Hand
65mo Cash Runway
Follow CTNM by email Get an email when CTNM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CTNM, unsubscribe in one click. Privacy

📣 What CTNM Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
PIPE-505 Sensorineural Hearing Loss Phase 1/2 · NCT04462198 Completed
PIPE-791 Dose A Idiopathic Pulmonary Fibrosis Phase 2 · NCT07284459 Recruiting
PIPE-791 Dose B Idiopathic Pulmonary Fibrosis Phase 2 · NCT07284459 Recruiting
PIPE-307 Multiple Sclerosis Phase 1 · NCT04941781 Completed
PIPE-791 Chronic Osteoarthritis Pain Phase 1 · NCT06810245 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CTNM holds $244.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $11.3M/quarter from operations, an estimated runway of 65 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 32 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CTNM files for a raise →

👥 Who Owns CTNM

Insiders 0.7% Other 5%+ holders 15.9% Institutions (154 holders) 83.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 2,610,248 11.30% 2026-09-30
BALYASNY ASSET MANAGEMENT L.P. Institution (13G, 5%+) 2,420,948 10.48% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 2,049,493 8.87% 2026-06-30
Johnson & Johnson Innovation - JJDC, Inc 5%+ holder (13G) 1,979,173 8.57% 2026-11-03
Franklin Resources, Inc. Institution (13G, 5%+) 1,879,367 8.14% 2025-12-31
Franklin Templeton, Inc. Institution (13G, 5%+) 1,704,550 7.38% 2026-09-30
Squadron Master Fund LP 5%+ holder (13G) 1,700,000 7.36% 2026-10-21
Trails Edge Capital Partners, LP Institution (13G, 5%+) 1,679,443 7.27% 2026-09-22
Daniel S. Lorrain
Chief Scientific Officer · +39,757 options
Insider 145,312 0.63% 2026-07-08
Carmine N. Stengone
CEO and President, Director · +837,847 options
Insider 17,217 0.07% 2026-09-08
Tim Watkins
CMO & Head of Development · +398,334 options
Insider 8,961 0.04% 2026-06-30

Share count 23,099,173 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CTNM picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CTNM and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.